Glenmark Pharmaceuticals Ltd announced on Monday that it has successfully acquired the generic version of Acetylcysteine injection from Aspen Pharma USA Inc. Following the acquisition, Glenmark launched the product immediately into the US market. Financial details of the transaction remain undisclosed.
Acquisition Details and Product Specifications
According to the official statement by Glenmark Pharmaceuticals, its US subsidiary, Glenmark Pharmaceuticals Inc. USA, acquired the Abbreviated New Drug Application (ANDA) for Acetylcysteine Injection. The acquired product comes in the strength of 6 gm/30 mL (200 mg/mL), packaged in single-dose vials.Acetylcysteine injection is prominently used for the emergency treatment of acetaminophen overdose, a common cause of medication-related poisoning.
Glenmark Pharmaceuticals' newly acquired Acetylcysteine injection matches the therapeutic efficacy of Cumberland Pharmaceuticals Inc's brand, Acetadote Injection (6 gm/30 mL, 200 mg/mL), which is the listed reference drug product in the US market.
Strengthening Injectable Portfolio in the US Market
Commenting on the strategic acquisition, Marc Kikuchi, President & Business Head, North America at Glenmark Pharmaceuticals, stated, "This is a great addition to our injectable portfolio in the US market as we continue to drive growth for the hospital segment."The expansion into injectable generics is expected to enhance Glenmark's product offering and strengthen its market presence in the competitive hospital segment.
Last updated by a enewsx: